- Home
- SEER vs FBRX Comparison
SEER vs FBRX Comparison
Compare SEER & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- FBRX
- Stock Information
- Founded
- SEER 2017
- FBRX N/A
- Country
- SEER United States
- FBRX United States
- Employees
- SEER N/A
- FBRX N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- FBRX Health Care
- Exchange
- SEER Nasdaq
- FBRX Nasdaq
- Market Cap
- SEER 129.7M
- FBRX 125.9M
- IPO Year
- SEER 2020
- FBRX N/A
- Fundamental
- Price
- SEER $2.28
- FBRX $22.92
- Analyst Decision
- SEER Hold
- FBRX Strong Buy
- Analyst Count
- SEER 1
- FBRX 3
- Target Price
- SEER $3.00
- FBRX $77.58
- AVG Volume (30 Days)
- SEER 186.8K
- FBRX 110.1K
- Earning Date
- SEER 02-27-2025
- FBRX 11-14-2024
- Dividend Yield
- SEER N/A
- FBRX N/A
- EPS Growth
- SEER N/A
- FBRX N/A
- EPS
- SEER N/A
- FBRX N/A
- Revenue
- SEER $14,608,000.00
- FBRX N/A
- Revenue This Year
- SEER N/A
- FBRX N/A
- Revenue Next Year
- SEER $34.78
- FBRX N/A
- P/E Ratio
- SEER N/A
- FBRX N/A
- Revenue Growth
- SEER N/A
- FBRX N/A
- 52 Week Low
- SEER $1.51
- FBRX $4.11
- 52 Week High
- SEER $2.63
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- SEER 42.84
- FBRX 63.60
- Support Level
- SEER $2.20
- FBRX $17.76
- Resistance Level
- SEER $2.37
- FBRX $20.97
- Average True Range (ATR)
- SEER 0.11
- FBRX 2.69
- MACD
- SEER -0.04
- FBRX -0.62
- Stochastic Oscillator
- SEER 20.45
- FBRX 51.62
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).